Protein C Global Assay in the Evaluation of Women with Idiopathic Pregnancy Loss

Galit Sarig; Naomi Lanir; Ron Hoffman; Benjamin Brenner

doi:10.1055/s-0037-1613149

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 88(01): 32-36
DOI: 10.1055/s-0037-1613149

Review Article

Schattauer GmbH

Protein C Global Assay in the Evaluation of Women with Idiopathic Pregnancy Loss

Galit Sarig

¹Thrombosis and Hemostasis Unit, Rambam Medical Center, Haifa, Israel

,

Naomi Lanir

¹Thrombosis and Hemostasis Unit, Rambam Medical Center, Haifa, Israel

,

Ron Hoffman

¹Thrombosis and Hemostasis Unit, Rambam Medical Center, Haifa, Israel

,

Benjamin Brenner

¹Thrombosis and Hemostasis Unit, Rambam Medical Center, Haifa, Israel

› Author Affiliations

Abstract

Summary

Since the majority of thrombophilic defects in women with pregnancy loss are in the protein C pathway, we have prospectively determined the diagnostic value of a protein C global assay in 60 consecutive women with pregnancy loss compared to 61 controls. Protein C activation time normalized ratio (PCAT-NR) in pregnancy loss women was significantly lower than controls (0.74 ± 0.16 vs. 0.99 ± 0.2; P <0.0001). PCAT-NR lower than cut off level of 0.8 were found in 42/60 (70%) of PL women compared to 7/61 (11%) of controls (OR = 18.0, 95% CI: 6.3-53.4, P < 0.0001).

Cut-off level of 0.8 successfully identified all pregnancy loss women with abnormality in the protein C pathway (12 factor V Leiden, 7 APC-Resistance without factor V Leiden, 15 low levels of protein S and 1 of protein C). Moreover, PCAT-NR below 0.8 was documented in 15/29 (52%) of PL women without thrombophilic risk factor compared to 3/55 (5%) of controls (OR = 18.6, 95% CI: 4.2-95.2, P <0.0001).

These results suggest that ProC Global may be useful as a screening test for protein C pathway abnormalities and may serve as a new thrombophilic risk factor in women with pregnancy loss.

Keywords

Protein C pathway - thrombophilia - pregnancy loss

Full Text

References

References
1 Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks’ gestation: Associated placental pathologic features. Am J Obstet Gynecol 1995; 173: 1049-57.
2 Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 1994; 09: 1328-32.
3 Haywood L, Brown MD. Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol 1991; 34: 1-17.
4 Blumenfeld Z, Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril 1999; 72: 765-74.
5 Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-8.
6 Preston FE, Rosendaal FR, Walker ID, Brint E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJM. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
7 Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-3.
8 Grandone E, Margaglione M, Colaizzo D, d’Addedda M, Cappucci G, Vecchione G, Scianname N, Pavone G, Di Minno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal loss. Thromb Haemost 1997; 77: 822-4.
9 Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92: 489-90.
10 Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551-4.
11 Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
12 Meinardi JR, Middeldorp S, Kam PJ, Koopman MMW, van Pampus ECM, Hamulyak K, Prins MH, Büller HR, van der Meer FJM. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999; 130: 736-9.
13 Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999; 14: 1624-7.
14 Robert A, Eschwege V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon contortrix venom (ACV test): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-6.
15 Dati F, Hafner G, Erbes H, Prellwitz W, Kraus M, Niemann F, Noah M, Wagner C. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-23.
16 Tripodi A, Akhavan S, Asti D, Faioni EM, Mannucci PM. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway. Blood Coagul Fibrinolysis 1998; 09: 485-9.
17 Toulon P, Halbmeyer WM, Hafner G, Schmitt Y, Randgard B, Odpadlik M, Van Den Eynden C, Wagner C. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of European multicenter evaluation. Blood Coagul Fibrinolysis 2000; 11: 447-54.
18 Exner T. Diagnostic methodologies for circulating anticoagulants. Thromb Haemost 1995; 74: 338-44.
19 Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
20 Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-7.
21 Pickering W, Holmes Z, Regan L, Cohen H. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage. Br J Haematol 1998; 102: 250.
22 Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000; 74: 1196-9.
23 Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343 (14) 1015-18.
24 Gemmati D, Serino ML, Tognazzo S, Ongaro A, Moratelli S, Gilli G, Forini E, De Mattei M, Scapoli GL. The reduced sensitivity of the ProC® Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk. Blood Coagul Fibrinolysis 2001; 12: 691-7.
25 Taylor Jr FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97: 1685-8.
26 Liaw PC, Neuenschwander PF, Smirnov MD, Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000; 275: 5447-52.
27 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J. Gestational outcome of thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.